Agreements reached under this partnership
Capital and Business Alliance- 1
An exclusive license covering development, manufacturing and commercialization worldwide, excluding Japan and certain regions in the Asia-Pacific.
- 2
The right to receive milestone payments totaling up to US$275 million (approximately ¥43.0 billion), depending on development and commercialization progress, as well as tiered royalties.
- 3
Hold a certain number of shares in the company.
- 4
Patrick Folsch (パトリック・フォルシュ), our CSO and President of Nxera Pharma UK, will change from not serving as a director to serving as a director of the company.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
The impact of this transaction on our consolidated results for the fiscal year ending December 2026 has already been reflected in the consolidated earnings forecast for the current fiscal year disclosed on 13 February 2026.
| Item | Details |
|---|---|
| Alliance partner's business activities | A business focused on accelerating preclinical trials and advancing development toward the initiation of global clinical trials for GPCR target programs created using NxWave™. |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | An exclusive license covering development, manufacturing and commercialization worldwide, excluding Japan and certain regions in the Asia-Pacific., The right to receive milestone payments totaling up to US$275 million (approximately ¥43.0 billion), depending on development and commercialization progress, as well as tiered royalties., Hold a certain number of shares in the company., Patrick Folsch (パトリック・フォルシュ), our CSO and President of Nxera Pharma UK, will change from not serving as a director to serving as a director of the company. |
| Dispatch of directors and officers | Patrick Folsch (パトリック・フォルシュ), our CSO and President of Nxera Pharma UK, will change from not serving as a director to serving as a director of the company. |
| Shareholding Policy | We will hold a certain number of shares in the company. Long-term holding, lock-up and transfer restrictions: not disclosed |
| Contract Date | 11 May 2026 |
| Impact on Business Performance | The impact of this transaction on our consolidated results for the fiscal year ending December 2026 has already been reflected in the consolidated earnings forecast for the current fiscal year disclosed on 13 February 2026. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To enable the company to accelerate preclinical trials and advance development toward the initiation of global clinical trials. In addition, to develop programs outside our core areas under external capital and management and maximize the value of the programs.